



# Assessing Psoriasis Severity

## The Classification of Psoriasis Severity by the Commonly Used Conventional Clinical Measures Can Be Incongruent With the Patients' Perception of Their Disease Severity<sup>3,4</sup>

- This disconnect may be because of the inability of conventional clinical measures to capture certain factors that contribute to disease severity<sup>1-3</sup>

### Factors Assessed by Conventional Clinical Measures<sup>2,5-7</sup>

	BSA	PASI	sPGA
Area of skin affected	✓	✓	✗
Severity of lesions	✗	✓	✓
Differential impact of special areas (eg, scalp)	✗	✗	✗
Differential impact of symptoms (eg, itch)	✗	✗	✗
Patient-reported outcomes	✗	✗	✗
Patient perspectives	✗	✗	✗

# BSA

is the **most commonly used clinical measure** for determining whether a patient has moderate psoriasis among US dermatologists<sup>4,\*</sup>

# 41%

of US dermatologists **do not consider the location of the skin areas** affected by psoriasis when determining whether a patient has moderate psoriasis<sup>4,\*</sup>

# 39%

of patients with **moderate skin involvement** perceive their disease to be **severe at its worst**<sup>3,†,‡</sup>

\*In a 2015 online survey of 150 US dermatologists; †MAPP was a population-based survey of 3,426 patients and 781 physicians in North America and Europe that aimed to determine the impact of psoriasis and psoriatic arthritis on HRQoL and to identify unmet treatment needs; ‡Moderate psoriasis is defined as a BSA of 4%–10%.

sPGA = static Physician's Global Assessment.

### References

1. Van Voorhees AS, et al. *The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options*. 6th ed. [www.psoriasis.org/physician-member-benefits-portal/](http://www.psoriasis.org/physician-member-benefits-portal/). Accessed March 9 2021; 2. Menter A, et al. *J Am Acad Dermatol*. 2019;80:1029-1072; 3. Lebwohl MG, et al. *J Am Acad Dermatol*. 2014;70:871-881, e1-e30; 4. Knuckles MLF, et al. *J Dermatolog Treat*. 2018;29:658-663; 5. Feldman SR, et al. *Ann Rheum Dis*. 2005;64(suppl 2):ii65-ii68; 6. Gottlieb AB, et al. *J Am Acad Dermatol*. 2015;72:345-348; 7. Merola JF, et al. *Dermatol Ther*. 2018;31:e12589.